Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Depreciation and Depletion: 2012-2025

Historic Depreciation and Depletion for Ligand Pharmaceuticals (LGND) over the last 6 years, with Sep 2025 value amounting to $172,000.

  • Ligand Pharmaceuticals' Depreciation and Depletion fell 76.63% to $172,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 33.47%. This contributed to the annual value of $2.3 million for FY2024, which is 20.69% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Depreciation and Depletion is $172,000, which was down 34.85% from $264,000 recorded in Q2 2025.
  • Ligand Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $736,000 during Q3 2024, with a 5-year trough of $172,000 in Q3 2025.
  • Over the past 2 years, Ligand Pharmaceuticals' median Depreciation and Depletion value was $513,000 (recorded in 2025), while the average stood at $464,143.
  • Data for Ligand Pharmaceuticals' Depreciation and Depletion shows a maximum YoY crashed of 76.63% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Ligand Pharmaceuticals' Depreciation and Depletion stood at $389,000 in 2024, then plummeted by 76.63% to $172,000 in 2025.
  • Its last three reported values are $172,000 in Q3 2025, $264,000 for Q2 2025, and $513,000 during Q1 2025.